文献速递眼底病与葡萄膜炎

新生血管性年龄相关性黄斑变性首诊后十年生存趋势

Ten-year survival trends of neovascular age-related macular degeneration at first presentation.
PubMed 文献 · Br J Ophthalmol · 2020-10-03

该回顾性队列研究纳入103例未经治疗的首发眼新生血管性年龄相关性黄斑变性患者,评估抗VEGF治疗后的10年视力、解剖结局及治疗负担。结果显示,起始抗VEGF治疗后视力降至≤35个ETDRS字母的中位时间为37.8个月,达到≥70个字母的中位时间为8.3个月;末次随访时首发眼BCVA≤35和≥70字母的比例分别为41.1%和21%,而较好眼分别为5.4%和48.2%。

要点

  • 首发眼10年内约五分之一保留良好视力(BCVA≥70字母),较好眼约半数保留良好视力。
  • 首发眼视力降至≤35字母的中位时间为37.8个月,达到≥70字母的中位时间为8.3个月。
  • 每眼平均注射37.0±24.2次,患者水平平均53.6±30.1次,63.1%患者需双眼注射。

核心结论

  • 新生血管性年龄相关性黄斑变性的慢性病程及管理强调长期视力预后的重要性。
  • 约五分之一患者首发眼在起始抗VEGF治疗10年后保留良好视力(BCVA≥70 ETDRS字母),约半数患者较好眼保留良好视力。
  • 数据提示早期治疗新生血管性年龄相关性黄斑变性与更好的视力结局相关。

研究设计与样本

  • 回顾性队列研究,纳入2009年1月1日前开始雷珠单抗治疗的未经治疗、首发眼新生血管性年龄相关性黄斑变性患者103例。

主要发现

  • Kaplan-Meier分析显示,起始抗VEGF治疗后视力降至≤35个ETDRS字母的中位时间为37.8个月(95%CI 22.2至65.1)。
  • 视力达到≥70个ETDRS字母的中位时间为8.3个月(95%CI 4.8至20.9)。
  • 末次随访时,首发眼BCVA≤35字母和≥70字母的比例分别为41.1%和21%。
  • 较好眼BCVA≤35字母和≥70字母的比例分别为5.4%和48.2%。
  • 每眼平均注射次数为37.0±24.2次,患者水平平均为53.6±30.1次,63.1%的患者需要双眼注射。

关键数值与推荐

  • 主要结局为起始抗VEGF治疗后最佳矫正视力(BCVA)降至≤35个ETDRS字母的时间。
  • 次要结局包括BCVA达到≥70个字母的时间、10年内BCVA≥70和≤35字母的比例、BCVA和中心视网膜厚度的10年平均趋势及平均注射次数。

临床怎么用

  • 临床应重视新生血管性年龄相关性黄斑变性患者的长期随访与治疗负担管理。
  • 早期启动抗VEGF治疗可能有助于改善新生血管性年龄相关性黄斑变性患者的视力结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To describe 10-year trends in visual outcomes, anatomical outcomes and treatment burden of patients receiving antivascular endothelial growth factor (anti-VEGF) therapy for neovascular age-related macular degeneration (nAMD). METHODS: Retrospective cohort study of treatment-naïve, first-affected eyes with nAMD started on ranibizumab before January 1, 2009. The primary outcome was time to best-corrected visual acuity (BCVA) falling ≤35 ETDRS letters after initiating anti-VEGF therapy. Secondary outcomes included time to BCVA reaching ≥70 letters, proportion of eyes with BCVA ≥70 and ≤35 letters in 10 years, mean trend of BCVA and central retinal thickness over 10 years, and mean number of injections. RESULTS: For our cohort of 103 patients, Kaplan-Meier analyses demonstrated median time to BCVA reaching ≤35 and ≥70 letters were 37.8 (95% CI 22.2 to 65.1) and 8.3 (95% CI 4.8 to 20.9) months after commencing anti-VEGF therapy, respectively. At the final follow-up, BCVA was ≤35 letters and ≥70 letters in 41.1% and 21%, respectively, in first-affected eyes, while this was the case for 5.4% and 48.2%, respectively, in a patient's better-seeing eye. Mean injection number was 37.0±24.2 per eye and 53.6±30.1 at patient level (63.1% of patients required injections in both eyes). CONCLUSIONS: The chronicity of nAMD disease and its management highlights the importance of long-term visual prognosis. Our analyses suggest that one in five patients will retain good vision (BCVA ≥70 ETDRS letters) in the first-affected eye at 10 years after starting anti-VEGF treatment; yet, one in two patients will have good vision in their better-seeing eye. Moreover, our data suggest that early treatment of nAMD is associated with better visual outcomes.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Arpa C, Khalid H, Chandra S, et al. Ten-year survival trends of neovascular age-related macular degeneration at first presentation. Br J Ophthalmol. 2020. PMID: 33011683. doi:10.1136/bjophthalmol-2020-317161

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。